These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22429872)

  • 1. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study.
    Van Holten TC; Roest M; Riphagen J; Jansen C; Naarding P; Adriaansen HJ; De Groot PG; Remijn JA
    J Thromb Haemost; 2012 Jun; 10(6):1177-9. PubMed ID: 22429872
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between mean platelet volume and major depression.
    Varol E; Akpinar A
    J Clin Psychopharmacol; 2013 Oct; 33(5):723. PubMed ID: 23948792
    [No Abstract]   [Full Text] [Related]  

  • 3. Citalopram: new indication. No advantage.
    Prescrire Int; 1999 Feb; 8(39):18-9. PubMed ID: 10557570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
    Sanchez C; Reines EH; Montgomery SA
    Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos.
    Figueras G; Pérez V; San Martino O; Alvarez E; Artigas F
    Biol Psychiatry; 1999 Aug; 46(4):518-24. PubMed ID: 10459402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Increased perioperative blood loss during treatment with paroxetine].
    Sewnath ME; van Hillegersberg R; Koopman MM; Levi MM; Gouma DJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(38):1800-2. PubMed ID: 12369443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
    van Kerkhoven LA; Laheij RJ; Jansen JB
    Gut; 2007 May; 56(5):733; author reply 733. PubMed ID: 17440190
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
    van Zyl LT; Lespérance F; Frasure-Smith N; Malinin AI; Atar D; Laliberté MA; Serebruany VL
    J Thromb Thrombolysis; 2009 Jan; 27(1):48-56. PubMed ID: 18188512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels.
    Yoshimura R; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Nakamura J
    J Clin Psychopharmacol; 2010 Feb; 30(1):82-3. PubMed ID: 20075657
    [No Abstract]   [Full Text] [Related]  

  • 13. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mean platelet volume in patients with major depression: effect of escitalopram treatment.
    Ataoglu A; Canan F
    J Clin Psychopharmacol; 2009 Aug; 29(4):368-71. PubMed ID: 19593177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities.
    Andiné P; Rönnbäck L; Järvholm B
    Acta Psychiatr Scand; 1997 Jul; 96(1):82-3. PubMed ID: 9259230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
    Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
    Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxetine versus citalopram treatment of pathological crying after brain injury.
    Müller U; Murai T; Bauer-Wittmund T; von Cramon DY
    Brain Inj; 1999 Oct; 13(10):805-11. PubMed ID: 10576464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram (Lexapro) for depression.
    Masilamani S; Ruppelt SC
    Am Fam Physician; 2003 Dec; 68(11):2235-6. PubMed ID: 14677669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism.
    Abdelmalik N; Ruhé HG; Barwari K; van den Dool EJ; Meijers JC; Middeldorp S; Büller HR; Schene AH; Kamphuisen PW
    J Thromb Haemost; 2008 Dec; 6(12):2168-74. PubMed ID: 18983505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.